Introduction
============

Tanshinones are a class of abietane diterpene compounds extracted from the well-known Chinese herbal plant, *Salvia miltiorrhiza* (Red sage or Chinese sage or Danshen) viz., a perennial plant with a height between 90 to 1,200 m, and which is highly valued for its roots which are religiously employed for medical purposes in traditional Chinese medicinal practices ([@b1-etm-0-0-7679]). The plant is a 'part and parcel' of the Chinese and the Japanese territories and usually grows in grassy, yet mushy locations, such as forests or hillsides ([@b2-etm-0-0-7679]). This herb has been already tested for the treatment of chronic obstructive pulmonary disease (COPD), and has shown to be highly effective ([@b3-etm-0-0-7679],[@b4-etm-0-0-7679]). Moreover, the abietane-type diterpene compound, tanshinone, has been used as a therapeutic remedy for a myriad of diseases, such as coronary artery and vascular diseases, stroke, hyperlipidemia, endangiitis, arthritis and hepatitis ([@b5-etm-0-0-7679]). The compound has also been employed for the treatment of breast cancer and inflammatory disorders ([@b1-etm-0-0-7679]). This study examined the anti-inflammatory properties of this compound.

Inflammation usually occurs when the body comes into contact with any harmful pathogen, irritant or when cell damage occurs. This type of inflammation is simply a function of self-defense, or it can occur as a protective mechanism of the body ([@b6-etm-0-0-7679]). With the help of an exhaustive literature recapitulation, it can be discerned that there are \>100 compounds which have been screened from *Salvia miltiorrhiza* and have been classified as per their chemical properties and structural capabilities. There are basically two categories in which the classification has been laid down: i) Water-soluble compounds, which comprise compounds, such as salvianolic A-G and lithospermic acid B; and ii) lipid-soluble category compounds which encapsulate the compounds tanshinone IIA, dihydrotanshinone I (<https://pubchem.ncbi.nlm.nih.gov/compound/11425923>; <https://toxnet.nlm.nih.gov/cgi-bin/sis/search2/r?dbs+hsdb:@term+@rn+@rel+87205-99-0>) and cryptotanshinones (<https://pubchem.ncbi.nlm.nih.gov/compound/160254>) ([@b7-etm-0-0-7679],[@b8-etm-0-0-7679]). The lipid-soluble categories of the compounds have been shown to have anti-inflammatory properties ([@b5-etm-0-0-7679]).

In this study, we focused our attention on tanshinone compounds which have the potential to act as anti-inflammatory agents for various inflammation-based diseases. Furthermore, we targeted these compounds for a molecular docking and interaction analyses to their counterpart proteins. The basic mode of operation of this study has been showcased in the form of a flowchart as shown in [Fig. 1](#f1-etm-0-0-7679){ref-type="fig"}.

Materials and methods
=====================

### Compounds

Query tanshinone compounds were retrieved from the ChEMBL database ([@b9-etm-0-0-7679]) along with their target proteins. A list of the query compounds and their target proteins is presented in [Tables I](#tI-etm-0-0-7679){ref-type="table"}--[V](#tV-etm-0-0-7679){ref-type="table"}. An extensive literature recapitulation was accomplished in order to search for lipid-soluble compounds, and in particular for tanshinone compounds. Initially, 18 compounds were retrieved which exhibited anti-inflammatory acitivity ([@b5-etm-0-0-7679]). An exhaustive filtering was carried out so as to retrieve the best, optimal and specific tanshinone compounds. By using the ChEMBL database, 4 best keyword matching the compounds were obtained namely, tanshinone IIA (CHEMBL187266), tanshinone IIA sulfone (CHEMBL1473252), dihydrotanshinone I (CHEMBL227075) and crytotanshinone (CHEMBL187460). Out of these 4, only 2, dihydrotanshinone I and cryptotanshinone were selected for further analysis as they had a greater number of similar target proteins.

### Determination of pharmacokinetic and pharmacodynamic properties and bioactivity of tanshinone compounds

The acknowledgement of the binding of tanshinone compounds to their target proteins was accomplished using Molinspiration (<http://www.molinspiration.com/cgi-bin/properties>) and DrugBank ([@b10-etm-0-0-7679],[@b11-etm-0-0-7679]). ADME expands to Absorption, Distribution, Metabolism and Excretion. ADME properties plays pivotal role during the process of drug design due to the fact that these account for the failure of approximately 60% of all drugs during clinical phases. Traditionally, these properties are assessed at the end of the drug development process, but now-a-days it is applied at an early phase in order to filter out molecules with poor ADME properties. DrugBank ([@b10-etm-0-0-7679],[@b11-etm-0-0-7679]) is an inclusive, open and freely-available online database which encases information on drugs and their targets. It a type of encyclopedia of drugs. Molinspiration is a cheminformatics tool, which is an online based tool used to calculate molecular properties, such as molecular weight, the number of atoms, the number of hydrogen donor atoms, the number of hydrogen acceptor atoms, and the polar surface area, of small molecules (<http://www.molinspiration.com/cgi-bin/properties>).

### Active site prediction and docking analysis

Active site prediction is a state-of-the-art approach which helps in the determination of the sites/pockets/clefts in the protein structures, where any ligand or any small molecule can bind to it. Once the binding cleft or pocket is known, docking determines their affinity and binding stability and root mean square deviation (RMSD) value, etc. Active Site prediction tools, such as TM Site ([@b12-etm-0-0-7679]), is a tool used for the identification of the ligand binding template sequences from the BioLip protein functional database ([@b13-etm-0-0-7679]) by utilizing profile sequence differentiation and by attaching sub-structures ([@b12-etm-0-0-7679]); COACH ([@b14-etm-0-0-7679]) provides reliable results which can be used for docking analyses or any other research; COFACTOR ([@b14-etm-0-0-7679]) begins from the tertiary structure of the protein and threads the protein query through the BioLip functional database using global and local matches to determine functional and active sites within the query protein ([@b14-etm-0-0-7679]); these were employed for the purposes of this study. An online docking server, Docking Server ([@b15-etm-0-0-7679]), which is based on AutoDock, was employed for docking purposes thereafter. This online server has an inbuilt parameter which allows the user to select the site of docking in the target protein

### Interaction analysis

After docking, many interactions are formed between a protein and its ligand, which are essential for the stability of the complex structure. The CCP4 tool ([@b16-etm-0-0-7679]) can be downloaded from the CCP4 suite from the main webpage (<http://www.ccp4.ac.uk/docs.php>. Once the tool is downloaded, the user finds that the tool has a simple GUI with a number of options, such as structural analysis, which again contains many options for studying the protein structures in detail ([@b16-etm-0-0-7679]). Protein Interaction Ligand Profiler (PLIP) ([@b17-etm-0-0-7679]), unlike other interactive tools, does not require any structural preparations and returns a list of interactions, mostly 7 types, such as hydrogen bonding, π-stacking, hydrophobic bonds, π-interactions and polar bonds.

Results
=======

### Pharmacokinetic, pharmacodynamic properties and bioactivity investigation

As a primary step towards confirming whether tanshinone compounds have the potential to be 'drug-like', i.e., it has properties such as solubility in water and other solvents, potency at the biological targets, ligand efficiency, and so on. It was exposed to Molinspiration prior to docking and interaction studies. The pharmacokinetic and physiochemical results are presented in [Table VI](#tVI-etm-0-0-7679){ref-type="table"}. Pre-ADME evaluation showcases that tanshinone compounds are very much 'drug-like' as it does not violate any thumb rule, such as Lipinski\'s, Ghose\'s, Veber\'s and Eden\'s rule. Dihydrotanshinone I and cryptotanshinone have quite similar molecular weights (278.3 and 296.3 kDa, respectively), and their topological surface area was also equivalent viz., 43.38. Cryptotanshinone had an edge when compared to dihydrotanshinone I, as it was a better ion channel modulator. The plasma membrane has a bi-lipid layer, and only substances which are semi-permeable or completely permeable can pass through it. Cryptotanshinone being a good ion channel modulator, can gain access easily through the plasma membrane and can reach the other parts of the body easily via the blood.

As regards their bioactivity, it can be discerned that both exhibit a good overall bioactivity; however, cryptotanshinone again surpasses dihydrotanshinone. Bioactivity heavily depends on whether the ligand of interest is a G-protein coupled receptor (GPCR) ligand or not. GPCRs are mandatory as to when an external signaling molecule (ligand) binds to a GPCR; it leads a conformational alteration in the GPCR triggering an affiliation between the GPCR and a nearby G protein. This interaction is mandatory for the protein to become activated, in turn leading to secondary messaging in the body ([@b16-etm-0-0-7679]). Cryptotanshinone is a better GPCR ligand (0.24) when compared to dihydrotanshinone I (0.03).

### AutoDock is a based online web-server; Docking Server was employed for docking

The results were obtained from this analysis may prove helpful in the opening of a new research avenues. It is known that the ligands, dihydrotanshinone I and cryptotanshinone hold a surface binding to 4 target proteins. [Figs. 2](#f2-etm-0-0-7679){ref-type="fig"} and [3](#f3-etm-0-0-7679){ref-type="fig"} showcase the surface binding of dihydrotanshinone I and cryptotanshinone with P23141, O00748, P22303 and Q9UBT6, which refers to the planar surface of the docking site of the target proteins. Furthermore, it hints to a rigid docking, which is surely a rare case. Interaction analysis discerned that the ligands carry out mainly 4 types of interactions with the receptor proteins namely, hydrogen bonds, hydrophobic interactions, polar bonds and π-π interactions. The complete docking affinities and energy estimates re provided in [Table VII](#tVII-etm-0-0-7679){ref-type="table"}, while interaction details are presented in [Table VIII](#tVIII-etm-0-0-7679){ref-type="table"}.

Many other interactions were formed apart from the ones mentioned in [Table VIII](#tVIII-etm-0-0-7679){ref-type="table"}. [Figs. 4](#f4-etm-0-0-7679){ref-type="fig"} and [5](#f5-etm-0-0-7679){ref-type="fig"} encapsulate the interaction plots for all the 4 target proteins with cryptotanshinone and dihydrotanshinone I, respectively. Exploration and exploitation are the two key factors in data analysis. HBD plots are simply interactive plots which show interactions of amino acid residues with the ligand. They help to understand the interaction quality between the receptors and ligands, which in turn helps to learn more about the flexible nature of the protein domains. The interactive plots shown in [Fig. 4](#f4-etm-0-0-7679){ref-type="fig"} clearly indicate that cryptotanshinone has a better affinity and binding to its target receptors. The interactions also suggest that the docking between cryptotanshinone and O00748, P22303, P23141 and Q9UBT6 is a flexible docking.

Discussion
==========

The in silico approach has aimed to place some credit on the anti-inflammatory-based herbal compound, tanshinone. Through various bioinformatics techniques, we can identify and modify the drugs that are useful for the treatment of inflammation, and this may lead to novel insight being obtained into new aspects of anti-inflammatory disorders, which are less known to society, indicating vindictively the fact that our how society carries a lackadaisical approach towards such issues. It is important to be up well informed and to carry out detailed investigations of the proteins involved in anti-inflammation and of the traditional herbal medications which are being used to treat this disorder. A great amount of knowledge has been gained which needs to be synergistically collated and discussed. A gateway of research for elucidating inflammation and its treatment using herbal medicines was the main lead in this study. More than 15 protein targets were retrieved out of which only 4 target receptors were selected and examined. Along with this, lipid-soluble compounds, which were specific to the tanshinone class, which are being used in the treatment of inflammation were also highlighted, out of which, 2 compounds, dihydrotanshinone I and cryptotanshinone were selected with an aim of providing a new research avenue for the elucidation of the detailed mechanisms responsible for the pathogenesis of inflammatory diseases. These are multi-faceted herbal compounds whose benefits can be extracted and can be utilized effectively for human well-being and healthcare. From the treatment of breast cancer to inflammatory diseases, a herbal medication can prove to be effective. It is surely their agrarian nature which makes these medications a 'blessing in disguise'. In this study, an imperforate strategy was laid down in order to recognize the abilities of dihydrotanshinone I and crytptotanshinone with their pharmacokinetic, pharmacodynamic and physiocochemical properties, and ultimately to expose the ligands and the receptors proteins to docking analysis and to determine the binding affinity. Moreover, interactions analyses were accomplished successfully to identify the interactions formed between both dihdrotanshinone I and cryptotanshinone, and the 4 target proteins.

The bioactivity properties and various other pharmacokinetic and pharmacodynamic analyses discerned that crytptotanshinone was more effective than dihydrotanshinone and was more 'drug-like' than its counterpart. It has a better solubility, permeability and holds potential for use as an anti-inflammatory agent.

Docking analysis and interaction analyses were performed and revealed that there is an affinity between cryptotanshinone and O00748, P23141 and Q9UBT6, and interactions such as hydrogen bonds, π-π bonds, hydrophobic bonds are formed between the ligand and the receptor proteins. Hydrogen bonding between the ligand and the proteins indicate that the complexes have a good stability.
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###### 

List of target proteins for tanshinone IIA.

  ChEMBL ID       Description                                                UniProt ID
  --------------- ---------------------------------------------------------- ----------------
  ChEMBL4832      Transcription initiation factor                            P52655
  ChEMBL3474      Phospholipase A2 grp IIA                                   P14555
  ChEMBL5841      Low affinity immunoglobulin gamma-Fc region receptor IIA   P12318
  ChEMBL2189151   Myosin-9                                                   P35579
  ChEMBL5616      Activin receptor type 2A                                   P27037
  ChEMBL3797012   Tubulin β-2A chain                                         Q13885
  ChEMBL4444      Vitamin Κ-dependent protein-C                              P04070
  ChEMBL1905      Fibronectin receptor β                                     P05556
  ChEMBL3885597   ITGB1-ITGA9 complex                                        PO5556, Q13797
  ChEMBL3430895   Integrin α-10/itegrin beta-1                               P05556, O75578
  ChEMBL3137278   Integrin α-1/β-1 complex                                   P05556, P56199
  ChEMBL1907599   Integrin α-4/β-1                                           P05556, P13612
  ChEMBL2111407   Integrin α-V/β-1                                           P05556, P06756
  ChEMBL3885596   ITGA-6-ITGB1 complex                                       P05556, P23229
  ChEMBL2095226   Integrin α-5/β-1                                           P05556, P08648

###### 

List of target proteins for tanshinone IIA sulfone.

  ChEMBL ID       Description                                                             UniProt ID
  --------------- ----------------------------------------------------------------------- ------------
  ChEMBL2265      Acyl coenzyme A: cholesterol acyltransferase                            P23141
  ChEMBL3180      Carboxylesterase 2                                                      O00748
  ChEMBL1293237   Bloom syndrome protein                                                  P54132
  ChEMBL220       Acetylcholinesterase                                                    P22303
  ChEMBL5365      DNA Pol kappa                                                           Q9UBT6
  ChEMBL5990      Breast cancer type I susceptibility protein                             P38398
  ChEMBL1795087   Ubiquitin carboxyl terminal hydrolase I                                 O94782
  ChEMBL2903      Archidonate 15-lipoxygenase                                             P16050
  ChEMBL4159      Endoplasmic reticulum-associated amyloid beta peptide binding protein   Q99714
  ChEMBL1293255   15-hydroxyprostaglandin dehydrogenase (NAD^+^)                          P15428
  ChEMBL340       Cytochrome P4503A4                                                      P08684
  ChEMBL3577      Aldehyde dehydrogenase1A1                                               P00352

###### 

List of target proteins for dihydrotanshinone I.

  ChEMBL ID       Description                                    UniProt ID
  --------------- ---------------------------------------------- ----------------
  ChEMBL2265      Acyl coenzyme A: cholesterol acyltransferase   P23141
  ChEMBL3180      Carboxylesterase 2                             O00748
  ChEMBL3166      Protein-tyrosine phosphatase 1C                P29350
  ChEMBL220       Acetylcholinesterase                           P22303
  ChEMBL5365      DNA Pol kappa                                  Q9UBT6
  ChEMBL3864      Protein-tyrosine phosphatase 2C                Q06124
  ChEMBL1907606   Mitogen-activated protein kinase ERK1/ERK2     P27361, P28482
  ChEMBL2094115   MAP Kinase 38 (Family protein)                 Q16539, P53778
  ChEMBL1075138   Tyrosyl DNA phosphodiesterase                  Q9NUW8

###### 

List of target proteins for cryptotanshinone.

  ChEMBL ID       Description                                          UniProt ID
  --------------- ---------------------------------------------------- ------------
  ChEMBL2265      Acyl coenzyme A: cholesterol acyltransferase         P23141
  ChEMBL3180      Carboxylesterase 2                                   O00748
  ChEMBL3166      Protein-tyrosine phosphatase 1C                      P29350
  ChEMBL220       Acetylcholinesterase                                 P22303
  ChEMBL5365      DNA Pol kappa                                        Q9UBT6
  ChEMBL3864      Protein-tyrosine phosphatase 2C                      Q06124
  ChEMBL2916      Telomerase reverse transcriptase                     O14746
  ChEMBL5027      Flap endonuclease 1                                  P39748
  ChEMBL6117      Tyrosine-protein phosphatase non-receptor type 9     P43378
  ChEMBL3521      Receptor type tyrosine-protein phosphatase F (LAR)   P10586
  ChEMBL3807      T-cell protein tyrosine phosphatase                  P17706
  ChEMBL3243      Leukocyte common antigen                             P08575
  ChEMBL1293236   ATP-dependent DNA helicase Q1                        P46063
  ChEMBL335       Protein tyrosine phosphatase 1B                      P18031
  ChEMBL2146312   Werner syndrome ATP-dependent helicase               Q14191

###### 

List of common target proteins for dihydrotanshinone I and cryptotanshinone.

  ChEMBL ID    Description                                    UniProt ID
  ------------ ---------------------------------------------- ------------
  ChEMBL2265   Acyl coenzyme A: cholesterol acyltransferase   P23141
  ChEMBL3180   Carboxylesterase 2                             O00748
  ChEMBL220    Acetylcholinesterase                           P22303
  ChEMBL5365   DNA Pol kappa                                  Q9UBT6

###### 

Bioactivity, pharmacokinetic and pharmacodynamic properties of dihydrotanshinone I and cryptotanshinone.

  A, Bioactivity                                                                                                                                
  ------------------------------------------------------- ------------ ---------- ------------ -------- --------- ----------- ----------------- ------------
  Dihydrotanshinone I                                     0.03         0.00       0.04         0.09     −0.15     0.28                          
  Cryptotanshinone                                        0.24         0.36       −0.07        0.31     −0.14     0.46                          
                                                                                                                                                
                                                                                                                                                
  **B, Pharmacokinetic and pharmacodynamic properties**                                                                                         
                                                                                                                                                
  **Compound**                                            **miLogP**   **TPSA**   **natoms**   **MW**   **nON**   **nOHNH**   **nViolations**   **Volume**
                                                                                                                                                
  Dihydrotanshinone I                                     3.51         43.38      21           278.3    3         0           0                 247.4
  Cryptotanshinone                                        3.83         43.38      22           296.3    3         0           0                 276.1

###### 

Binding affinities and free energy estimation of the docked cryptotanshinone and dihydrotanshinone I to its target proteins.

  A, Cryptotanshinone                                                                                                                                                                                                    
  ---------------------------- ----------------------------------- ---------------------------------------- ------------------------------- -------------------------- --------------------------------- --------------- -----------------------
  O00748                       −5.24 kcal/mol                      145.24 µM                                −5.09 kcal/mol                  −0.14 kcal/mol             −5.24 kcal/mol                    100%            638.763
  P23141                       −7.06 kcal/mol                      6.68 µM                                  −7.11 kcal/mol                  +0.05 kcal/mol             −7.06 kcal/mol                    100%            46.8.499
  P22303                       −5.78 kcal/mol                      57.64 µM                                 −5.69 kcal/mol                  −0.09 kcal/mol             −5.78 kcal/mol                    100%            441.5
  Q9UBT6                       −0.51 kcal/mol                      425.86 µM                                −0.36 kcal/mol                  −0.14 kcal/mol             −0.51 kcal/mol                    10%             430.213
                                                                                                                                                                                                                         
  **B, Dihydrotanshinone I**                                                                                                                                                                                             
                                                                                                                                                                                                                         
  **Target protein**           **Estimated free binding energy**   **Estimated inhibition constant (Ki)**   **vDW+Hbond + desolv energy**   **Electrostatic energy**   **Total intramolecular energy**   **Frequency**   **Interact. surface**
                                                                                                                                                                                                                         
  O00748                       −4.59 kcal/mol                      428.85 µM                                −4.37 kcal/mol                  −0.22 kcal/mol             −4.59 kcal/mol                    100%            658.163
  P23141                       −3.88 kcal/mol                      1.44 µM                                  −3.90 kcal/mol                  +0.03 kcal/mol             −3.88 kcal/mol                    70%             482.697
  P22303                       −4.72 kcal/mol                      344.74 µM                                −4.75 kcal/mol                  +0.03 kcal/mol             −4.72 kcal/mol                    60%             455.875
  Q9UBT6                       +0.03 kcal/mol                        −                                      +0.37 kcal/mol                  −0.14 kcal/mol             −0.04 kcal/mol                    20%             416.477

###### 

Interactions formed by dihydrotanshinone I and cryptotanshinone with the receptor targets, O00748, P23141, P22303 and Q9UBT6.

  A, Dihydrotanshinone I                                                                                                                                                                                                                                                                                                                                                                                                                  
  ------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------ ------------------------------------
  O00748                                                                                                                                                                                                                                                                                                                                                                                                                                  
  O2()-ARG105               C1()-LEU55                                                                                                                                                                                                                                                                                                                     C1()-TYR52; C10()-TYR52; C14()-TYR52; C4()-HIS118; C6()-HIS118, C12()-HIS118   O2()-ARG88; O3()-ARG88; O3()-HIS11
  P23141                                                                                                                                                                                                                                                                                                                                                                                                                                  
                            C17()-LEU97; C15()-LEU97; C16()-LEU97; C17()-VAL146; C7()-VAL254; C6()-VAL254; C8()-VAL254; C18()-VAL254; C6()-LEU255; C7()\_LEU255; C5()-LEU318; C6()-LEU318; C15()-358; C1()-ILE359; C2()-ILE359; C13()-LEU362; C15()-ILE362, C16()-ILE362; C17()-ILE362; C8()-MET424; C18()-MET424; C18()-PHE425                            C2()-PHE425; C1()-HIS467; C2()-HIS467                                          O1()-HIS467
  P22303                                                                                                                                                                                                                                                                                                                                                                                                                                  
                            C18()-TYR77; C13()-PRO344; C16()-PRO344; C17()-PRO344                                                                                                                                                                                                                                                                                                                                                         
  Q9UBT6                                                                                                                                                                                                                                                                                                                                                                                                                                  
  O1()-ALA194               C18()-ALA186; C18()-PHE192; C1()-ALA194; C10()-ALA194; C14()-ALA194                                                                                                                                                                                                                                                            C3()-PHE192; C8()-PHE192; C1()-PHE192; C2()-PHE192; C7()-PHE192                
                                                                                                                                                                                                                                                                                                                                                                                                                                          
  **B, Cryptotanshinone**                                                                                                                                                                                                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                          
  **Hydrogen bonds**        **Hydrophobic bonds**                                                                                                                                                                                                                                                                                                          **π-π Interactions**                                                           **Polar bonds**
                                                                                                                                                                                                                                                                                                                                                                                                                                          
  O00748                                                                                                                                                                                                                                                                                                                                                                                                                                  
                            C19()-LEU97; C17()-LEU97; C18()-LEU97; C19()-VAL146; C7()-VAL254; C8()-VAL254; C13()-LEU304; C14()-LEU304; C5()-LEU318; C6()-LEU318; C17()-LEU358; C1()-ILE359, C9()-ILE359, C10()-ILE359; C17()-LEU362; C18()-LEU362; C19()-LEU362; C7()-LEU387; C9()-387; C7()-MET424; C8()-MET424; C9()-MET424; C10()-MET424; C1()-HIS467   C10()-PHE425                                                                   O1()-HIS467
  P23141                                                                                                                                                                                                                                                                                                                                                                                                                                  
                            C19()-LEU97; C17()-LEU97; C18()-LEU97; C19()-VAL146; C7()-VAL254; C8()-VAL254; C13()-LEU304; C14()-LEU304; C5()-LEU318; C6()-LEU318; C17()-LEU358; C1()-ILE359, C9()-ILE359, C10()-ILE359; C17()-LEU362; C18()-LEU362; C19()-LEU362; C7()-LEU387; C9()-387; C7()-MET424; C8()-MET424; C9()-MET424; C10()-MET424; C1()-HIS467   C10()-PHE425                                                                   O1()-HIS467
  P22303                                                                                                                                                                                                                                                                                                                                                                                                                                  
                            C13()-PRO344                                                                                                                                                                                                                                                                                                                                                                                                  
  Q9UBT6                                                                                                                                                                                                                                                                                                                                                                                                                                  
  O2()-LYS182               C19()-PHE192; C7()-MET193; C9()-MET193; C6()-MET193; C13()-ALA194                                                                                                                                                                                                                                                              C17()-PHE192; C18()-PHE192; C15()-PHE192                                       

[^1]: Contributed equally
